| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Bacterial ribosome (protein synthesis machinery). Althiomycin inhibits protein synthesis in bacteria. It is effective against E. coli at concentrations of 1 and 10 µg/mL but does not inhibit protein synthesis in isolated rabbit reticulocytes at 100 µg/mL, indicating selectivity for bacterial ribosomes. The compound is a thiopeptide antibiotic.
|
|---|---|
| ln Vitro |
Althiomycin demonstrates potent antibacterial activity in vitro against Gram-positive bacteria, with MICs of 25 µg/mL for S. aureus, 25 µg/mL for S. epidermidis, and 3.1 µg/mL for S. pyogenes. It inhibits protein synthesis in E. coli at concentrations of 1 and 10 µg/mL. The compound's antibacterial spectrum and potency have been characterized in various in vitro assays.
|
| ln Vivo |
In vivo, Althiomycin has been studied for its antibacterial efficacy in animal models of infection. However, detailed in vivo data are limited. The compound was originally isolated from Streptomyces and has been the subject of research due to its potent biological activity. It is not currently used clinically as an antibiotic.
|
| Enzyme Assay |
In vitro antibacterial assays for Althiomycin involve determining minimum inhibitory concentrations (MICs) against various bacterial strains. Bacteria are cultured in appropriate media and treated with Althiomycin at varying concentrations. MIC values are determined as the lowest concentration that inhibits visible bacterial growth. Protein synthesis inhibition assays are performed using cell-free translation systems or bacterial cultures.
|
| Cell Assay |
Cellular assays for Althiomycin are not typically performed, as the compound acts directly on bacterial ribosomes. However, bacterial cultures are used to assess antibacterial activity. Protein synthesis inhibition can be measured by incorporating radiolabeled amino acids into newly synthesized proteins in the presence of the compound.
|
| Animal Protocol |
In vivo animal studies for Althiomycin are not extensively documented. When performed, they typically involve murine models of bacterial infection. The compound is administered orally or intraperitoneally, and survival or bacterial clearance is assessed. However, detailed protocols and efficacy data are not widely available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Althiomycin are limited. The compound has a molecular weight of 439.47 and a molecular formula of C16H17N5O6S2. It is typically stored under recommended conditions. Detailed ADME parameters are not extensively documented. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicological data for Althiomycin are limited. The compound is an antibiotic and is intended for research use only, not for human therapeutic applications. Standard laboratory safety precautions should be taken when handling the compound. No specific toxicity data are available in publicly accessible sources.
|
| References |
[1]. Gerc, A.J., Song, L., Challis, G.L., et al. The insect pathogen Serratia marcescens Db10 uses a hybrid non-ribosomal peptide synthetase-polyketide synthase to produce the antibiotic althiomycin. PLoS One 7(9), e44673 (2012). [2]. Inami, K., and Shiba, T. Syntheses of althiomycin analogs in relation to antibacterial activities. Bull. Chem. Soc. Jpn. 59(7), 2185-2189 (1986). [3]. Fujimoto, H., Kinoshita, T., Suzuki, H., et al. Studies on the mode of action of althiomycin. J. Antibiot. (Tokyo) 23(6), 271-275 (1970). |
| Additional Infomation |
Abhidiomycin is a peptide antibiotic isolated from soil and intestinal bacteria. It is a protein synthesis inhibitor with antibacterial activity against both Gram-positive and Gram-negative bacteria. It is both a bacterial metabolite and an antibacterial agent and a protein synthesis inhibitor. Abhidiomycin belongs to the classes of antibiotics including 1,3-thiazoles, γ-lactams, aldoximes, pentapeptides, tertiary amides, secondary amides, primary alcohols, ethers, pyrroline derivatives, and peptides.
Althiomycin is a thiazole antibiotic from Streptomyces althioticus that is active against Gram-positive bacteria including S. aureus, S. epidermidis, and S. pyogenes. It inhibits bacterial protein synthesis. The compound is not approved for clinical use and is available for research purposes only. Its molecular formula is C16H17N5O6S2. |
| Molecular Formula |
C16H17N5O6S2
|
|---|---|
| Molecular Weight |
439.46
|
| Exact Mass |
439.062
|
| CAS # |
12656-40-5
|
| PubChem CID |
135434097
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.72g/cm3
|
| Index of Refraction |
1.768
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
773
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1CN(C(C2CSC(C(NC(C3=CSC(/C=N/O)=N3)=O)CO)=N2)=O)C(=O)C=1
|
| InChi Key |
VQQNQKXWJMRPHT-YNYXEJBLSA-N
|
| InChi Code |
InChI=1S/C16H17N5O6S2/c1-27-8-2-13(23)21(4-8)16(25)11-7-29-15(20-11)9(5-22)19-14(24)10-6-28-12(18-10)3-17-26/h2-3,6,9,11,22,26H,4-5,7H2,1H3,(H,19,24)/b17-3+/t9-,11+/m0/s1
|
| Chemical Name |
N-((S)-2-hydroxy-1-((S)-4-(4-methoxy-2-oxo-2,5-dihydro-1H-pyrrole-1-carbonyl)-4,5-dihydrothiazol-2-yl)ethyl)-2-((E)-(hydroxyimino)methyl)thiazole-4-carboxamide
|
| Synonyms |
Althiomycin, NSC-102809 Matamycin NSC 102809 NSC102809 116-A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2755 mL | 11.3776 mL | 22.7552 mL | |
| 5 mM | 0.4551 mL | 2.2755 mL | 4.5510 mL | |
| 10 mM | 0.2276 mL | 1.1378 mL | 2.2755 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
